Home

CARB-X, led by Boston University, is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines.

118+

$million

Invested

28

company

Projects

5

different

Countries

11

focused on new classes

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

SciBac is fighting fire with fire by using improved bugs as drugs

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners

Events

Events

06.20.19

San Francisco, CA

ASM Microbe 2019

06.24.19

San Francisco, CA

ASM Microbe Breakout Session - Enabling Academia to Fill the Discovery Gap

06.25.19

Stockholm, Sweden

International Council of Academies of Engineering and Technological Sciences (CAETS) Conference

CARB-X News

  • 06.17.2019  |  CARB-X awards Oxford Drug Design funding to develop a new class of antibiotics to treat drug-resistant Gram-negative infections full release

  • 05.14.2019  |  CARB-X funds Debiopharm to develop a new class of antibiotics to treat hospital-acquired pneumonia caused by multidrug-resistant superbug Acinetobacter baumannii full release

  • 04.30.2019  |  CARB-X launches new Funding Rounds to support the development of antibiotics, vaccines, diagnostics and other life-saving products that target drug-resistant bacteria full release

See All News

In The News

  • 06.14.2019  |  Seeking the Path of Least Resistance full story

  • 06.13.2019  |  Inside CARB-X, the Boston Fund on the Front Lines Fighting Antibiotic Resistance full story

  • 05.28.2019  |  The Radical Plan to Change How Antibiotics Get Developed full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.